Literature DB >> 22481131

Decision analysis, economic evaluation, and newborn screening: challenges and opportunities.

Lisa A Prosser1, Scott D Grosse, Alex R Kemper, Beth A Tarini, James M Perrin.   

Abstract

The number of conditions included in newborn screening panels has increased rapidly in the United States during the past decade, and many more conditions are under consideration for addition to state panels. The rare nature of candidate conditions for newborn screening makes their evaluation challenging. The scarcity of data on the costs of screening, follow-up, treatment, and long-term disability must be addressed to improve the evaluation process for nominated conditions. Decision analyses and economic evaluations can help inform policy decisions for newborn screening programs by providing a systematic approach to synthesizing available evidence and providing projected estimates of long-term clinical and economic outcomes when long-term data are not available. In this review, we outline the types of data required for the development of decision analysis and cost-effectiveness models for newborn screening programs and discuss the challenges faced when applying these methods in the arena of newborn screening to help inform policy decisions.Genet Med advance online publication 5 April 2012.

Entities:  

Year:  2012        PMID: 22481131      PMCID: PMC4485974          DOI: 10.1038/gim.2012.24

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  38 in total

1.  Waiving informed consent in newborn screening research: balancing social value and respect.

Authors:  Beth A Tarini; Wylie Burke; C Ronald Scott; Benjamin S Wilfond
Journal:  Am J Med Genet C Semin Med Genet       Date:  2008-02-15       Impact factor: 3.908

2.  Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US.

Authors:  John F P Bridges; Eberechukwu Onukwugha; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Primer on medical decision analysis: Part 2--Building a tree.

Authors:  A S Detsky; G Naglie; M D Krahn; D A Redelmeier; D Naimark
Journal:  Med Decis Making       Date:  1997 Apr-Jun       Impact factor: 2.583

Review 4.  Primer on medical decision analysis: Part 1--Getting started.

Authors:  A S Detsky; G Naglie; M D Krahn; D Naimark; D A Redelmeier
Journal:  Med Decis Making       Date:  1997 Apr-Jun       Impact factor: 2.583

5.  Comparative effectiveness research: a progress report.

Authors:  Harold C Sox
Journal:  Ann Intern Med       Date:  2010-08-02       Impact factor: 25.391

6.  Congenital toxoplasmosis--a report on the Danish neonatal screening programme 1999-2007.

Authors:  Dennis Röser; Henrik Vedel Nielsen; Eskild Petersen; Peter Saugmann-Jensen; Bent Nørgaard-Pedersen; Peter Bent Nørgaard-Pedersen
Journal:  J Inherit Metab Dis       Date:  2010-06-29       Impact factor: 4.982

Review 7.  Economics of tandem mass spectrometry screening of neonatal inherited disorders.

Authors:  Abdullah Pandor; Joe Eastham; James Chilcott; Suzy Paisley; Catherine Beverley
Journal:  Int J Technol Assess Health Care       Date:  2006       Impact factor: 2.188

Review 8.  Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations.

Authors:  Lisa A Prosser; James K Hammitt; Ron Keren
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

9.  Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency.

Authors:  B Wilcken; J Hammond; M Silink
Journal:  Arch Dis Child       Date:  1994-05       Impact factor: 3.791

10.  Long-term follow-up after diagnosis resulting from newborn screening: statement of the US Secretary of Health and Human Services' Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children.

Authors:  Alex R Kemper; Coleen A Boyle; Javier Aceves; Denise Dougherty; James Figge; Jill L Fisch; Alan R Hinman; Carol L Greene; Christopher A Kus; Julie Miller; Derek Robertson; Joseph Telfair; Brad Therrell; Michele Lloyd-Puryear; Peter C van Dyck; R Rodney Howell
Journal:  Genet Med       Date:  2008-04       Impact factor: 8.822

View more
  15 in total

1.  Predicting health utilities for children with autism spectrum disorders.

Authors:  Nalin Payakachat; J Mick Tilford; Karen A Kuhlthau; N Job van Exel; Erica Kovacs; Jayne Bellando; Jeffrey M Pyne; Werner B F Brouwer
Journal:  Autism Res       Date:  2014-09-25       Impact factor: 5.216

2.  The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.

Authors:  Scott D Grosse; John D Thompson; Yao Ding; Michael Glass
Journal:  Milbank Q       Date:  2016-06       Impact factor: 4.911

3.  Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing.

Authors:  Zoë P Mackay; Dmitry Dukhovny; Kathryn A Phillips; Alan H Beggs; Robert C Green; Richard B Parad; Kurt D Christensen
Journal:  Value Health       Date:  2020-03-20       Impact factor: 5.725

4.  Comparative effectiveness and child health.

Authors:  Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

5.  Exome/Genome-Wide Testing in Newborn Screening: A Proportionate Path Forward.

Authors:  Vasiliki Rahimzadeh; Jan M Friedman; Guido de Wert; Bartha M Knoppers
Journal:  Front Genet       Date:  2022-07-04       Impact factor: 4.772

6.  Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review.

Authors:  Aaron J Goldenberg; Anne Marie Comeau; Scott D Grosse; Susan Tanksley; Lisa A Prosser; Jelili Ojodu; Jeffrey R Botkin; Alex R Kemper; Nancy S Green
Journal:  Matern Child Health J       Date:  2016-03

Review 7.  Funding decisions for newborn screening: a comparative review of 22 decision processes in Europe.

Authors:  Katharina Elisabeth Fischer; Wolf Henning Rogowski
Journal:  Int J Environ Res Public Health       Date:  2014-05-19       Impact factor: 3.390

8.  Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges.

Authors:  Alex Root; Peter Allen; Paul Tempst; Kenneth Yu
Journal:  Cancers (Basel)       Date:  2018-03-07       Impact factor: 6.639

9.  Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening.

Authors:  Astrid Langer; Rolf Holle; Jürgen John
Journal:  BMC Health Serv Res       Date:  2012-09-04       Impact factor: 2.655

10.  Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis.

Authors:  Scott D Grosse
Journal:  Healthcare (Basel)       Date:  2015-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.